Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab

J Clin Oncol. 2012 Oct 1;30(28):e286-90. doi: 10.1200/JCO.2012.41.9911. Epub 2012 Aug 6.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Chemokine CCL11 / metabolism
  • Cytokines / metabolism
  • Erdheim-Chester Disease / drug therapy*
  • Erdheim-Chester Disease / metabolism
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / physiology

Substances

  • Antibodies, Monoclonal
  • Chemokine CCL11
  • Cytokines
  • Tumor Necrosis Factor-alpha
  • Infliximab